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Abstract: The increasing prevalence of non-alcoholic fatty liver disease (NAFLD) in adolescents is
challenging the global care system. No therapeutic strategies have been defined so far, and changes in
the lifestyle remain the only alternative. In this study, we assessed the protective effects of silymarin
in a juvenile non-alcoholic steatohepatitis (NASH) model and the in vitro effects on fat-laden human
hepatocytes. C57Bl/6 mice were exposed to HFHC diet immediately after weaning. After eight weeks,
animals showed histological signs of NASH. Silymarin was added to the HFHC diet, the treatment
continued for additional 12 weeks and the effects on BMI, hepatomegaly, visceral fat, lipid profile,
transaminases, HOMA-IR, steatosis, inflammation, fibrosis, oxidative stress, and apoptosis were
determined. The switch from HFHC to control diet was used to mimic lifestyle changes. In vitro
experiments were performed in parallel in human hepatocytes. HFHC diet supplemented with
silymarin showed a significant improvement in glycemia, visceral fat, lipid profile, and liver fibrosis.
Moreover, it reduced (both in vitro and in vivo) ALT, hepatic inflammation, oxidative stress, and
apoptosis. Lifestyle changes restored the control group parameters. The data presented show the
beneficial effects of the oral administration of silymarin in the absence of changes in the dietary habits
in a juvenile model of NASH.
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1. Introduction
The increasing prevalence of non-alcoholic fatty liver disease (NAFLD) worldwide is becoming
a challenge for the modern global care system [1]. While NAFL is a reversible and benign disorder,
the progression towards the more severe non-alcoholic steatohepatitis (NASH) must be not disregarded.
The booming prevalence of obesity and type 2 diabetes mellitus in young age and adolescence [2,3]
contributes not only to the onset of the condition but also provides more time for its evolution.
Therefore NASH incidence in children and adolescents represents the major threat to the upcoming
years. To date, there is no consensus concerning an effective pharmacological treatment for NASH, and
the only recomended treatment relies on lifestyle modifications [4] (diet [5] and physical activity [6–8]).
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However, the lack of compliance is still the main obstacle to overcome. Currently, drug interventions
are based on the association of several compounds as an attempt to reverse the co-morbidities of the
metabolic syndrome. The molecular mechanisms leading to fat accumulation, oxidative imbalance, and
liver fibrosis are the targets of the main classes of drugs usually associated with lifestyle modifications.
Unfortunately, to date none of the proposed drugs have provided solid results. Thus, there is an
evident need for the characterization of new therapeutic alternatives. Recent studies of food bioactive
compounds represent an attractive approach to be considered. Silymarin, extracted from plant
seeds and fruits of silybum marianum (commonly known as milk thistle [9,10]), has been used as
medicinal herb from as early as fourth century B.C. It has been widely employed in the treatment of
various liver disorders [11–13] due to its hepatoprotective properties such as anti-inflammatory [14],
anti-proliferative [15–17], immunomodulatory [18], and anticholesterolemic properties [19,20]. In
particular, silymarin has been widely proposed in the treatment of NASH although definitive data
have not been provided so far. Due to its low bioavailability [21,22], some solubilizing compounds
(phosphatidycholine; β-cyclodextrin, vitamin E) were added to the plant extracts to enhance intestinal
absorption [23]. Although data obtained in animal models [24] are promising, the administration
and the dosage are often difficult to be reproduced in humans. On the other hand, data from clinical
trials using silymarin [25,26] are controversial and the real efficacy has been questioned for years. The
main limitations are the lack of silymarin standardization among its various formulations and the
still undefined effective dosage [27]. This situation is even worse among the pediatric and juvenile
population, where the available information is scarce. Studies of dietary supplements in children have
shown inconsistent effects to benefit children with NAFLD [28].
A good therapeutic approach to overcome the reticence towards lifestyle changes would be
the use of silymarin as a dietary supplement. Thus, the aim of the present study is to assess the
hepatoprotective effects of silymarin in an in vivo mouse model of juvenile NASH [29] and to determine
the direct effect on human fat-laden hepatocytes in an in vitro model [30]. The novelty of our work
relies on the use of a juvenile model of NASH (where males and females were considered as different
experimental groups) to assess the effect of silymarin administrated orally, incorporated in the western
diet, and in vitro together with free-fatty acids (FFA) as a strategy to prevent/revert the damage related
to the high fat and high carbohydrate (HFHC) diet.
2. Materials and Methods
2.1. Experimental Set-Up
2.1.1. Animal Model (In Vivo)
C57Bl/6 mice pups (28 of each sex) were obtained from Harlan Laboratories S.R.L. (S.Piero al
Natisone, Italy). Immediately after weaning, animals were randomly group-housed in cages based on
the final experimental protocol (Scheme 1) in a temperature-controlled environment (22 ◦C ± 2 ◦C)
and on a 12 h light/dark schedule, and fed ad-libitum with control diet (CTRL, D12328, Research
Diets, New Brunswick, NJ, USA) or HFHC diet (HFHC: D12331, Research Diets, New Brunswick, NJ,
USA) plus 42 g/L fructose/sucrose in drinking water, for a total of eight weeks (time required for
the onset of NASH, as described previously [29]). After eight weeks, a group of animals continued
with the HFHC; another group was fed with HFHC silymarin-enriched diet (added into the food
pellet (33 mg/kg/diet) (HFHC + SIL) (see section below)), in a third group diet was switched from
HFHC to CTRL diet (HFHC→CTRL) which represent the alimentary lifestyle changes, and in a fourth
group the switch of diet from HFHC to CTRL was enriched with silimarin (HFHC→CTRL + SIL) to
assess and eventual synergic effect of silymarin with lifestyle changes . The experimentation then
continued for a further 12 weeks (Scheme 1). Animals were sacrificed at the end of the trial. After O/N
fasting, animals were deeply anesthetized (Zoletil 10 mg/kg and Xilazine 5 mg/kg of body weight,
intra-peritoneal). Blood was collected by cardiac puncture (exsanguination). Whole blood was allowed
to clot at room temperature (RT) for 20 min, followed by centrifugation at 3500× g for 5 min at RT to
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separate the serum. All experimental protocols were approved by the local committee of the Medical
Research Institute and by the National Authority (Ministero della Salute-Direzione Generale della
Sanità Animale e dei Farmaci Veterinary—Ufficio VI, Rome, Italy. Approval 11072013). They are in
accordance with FELASA guidelines and the National law for Laboratory Animal Experimentation
(D. lgs 116/92, article 7). The maximal effort was made to reduce the number of animals used and
their sufferance in the respect of the 3R rule (Reduction, Refinement and Replacement).
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of animals continued with HFHC, whereas in others HFHC diet was switched to silymarin-
formulated HFHC (HFHC+SIL) (cyan arrow), to CTRL (HFHC→CTRL) diet (orange arrow) and to 
CTRL plus the addition of silymarin (HFHC→CTRL+SIL) (green arrow). The trial continued until 
week 20. 
2.1.2. HFHC+Silymarin Food Formulation 
To follow a physiological administration, silymarin extract (Sigma Aldrich, St. Luois, MO, USA) 
containing 210 mg/g of silybin was added into the HFHC diet and administrated orally. Briefly, the 
composition of the animal food provided by Research Diets Inc. (Research Diets, New Brunswick, 
NJ, USA) and designed for a high fat high carbohydrates diet (HFHCD) was modified opportunely 
to include silymarin in the product (D12331, 23% protein, 35.5% carbohydrate, 35.8% fat in form of 
soybean oil and hydrogenated coconut oil). In particular, silymarin powder (0.01 g/g) and Tween 80 
(Sigma Aldrich, St. Luois, MO, USA) (0.1 g/g) were added to coconut oil (Unigrà, Conselice, Italy) 
previously heated at 40 °C. The system was maintained at 40 °C until silymarin complete 
solubilization. The oil enriched with silymarin was manually incorporated at a concentration of 14% 
by weight in paste obtained by grounding the animal feed pellet with a mixer (Kenwood, Prospero 
KM260, Havant, UK). Subsequently, silymarin-enriched paste was subdivided in aliquots of 4.5 g 
cylinders. The effective concentration of the bioactive principle (silybin) contained in each food 
cylinder was (270 mg/kg) determined by HPLC analysis.  
2.1.3. Cellular In Vitro Model 
Silibinin is the major component (50–60%) of the silymarin extract and is characterized by an 
equimolar combination of two diasteroisomers, called silybin A and B [31]. The use of mice primary 
hepatocytes was excluded as an attempt to reduce the number of animals in the experimentation. 
Thus, the translation of the direct effect of silybin on human hepatocytes was assessed in vitro, by 
using stabilized hepatic cell lines. The hepatic cell line (HuH7) (JHSRRB, Cat#JCRB0403), obtained 
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2.1.2. HFHC + SILymarin Food Formulation
To follow a physiological administration, silymarin extract (Sigma Aldrich, St. Luois, MO, USA)
containing 210 mg/g of silybin was added into the HFHC diet and administrated orally. Briefly, the
composition of the animal food provided by Research Diets Inc. (Research Diets, New Brunswick,
NJ, USA) and designed for a high fat high carbohydrates iet (HFHCD) was modified opportunely
t include silymarin in the pr uct (D12331, 23% protein, 35.5% carbohydrate, 35.8% fat in form of
soybean oil an hydrogenated coconut oil). In particular, silymarin powder (0.01 g/g) and Twee 80
(Sigma Aldrich, St. Luois, MO, USA) (0.1 g/g) were added to coconut oil (Unigrà, Conselice, Italy)
previously heated at 40 ◦C. The system was maintained at 40 ◦C until silymarin complete solubilization.
The oil enriched with silymarin was manually incorporated at a conce tration of 14% by weight in paste
obtained by grounding the animal feed pellet ith a mixer (Kenwood, Prospero KM260, Havant, UK).
Subsequently, silymari -enriched paste was subdivided in aliquots of 4.5 g cylinders. The effective
concentration of the bioactive principle (silybin) contained in each food cylinder was (270 mg/kg)
determined by HPLC analysis.
2.1.3. Cellular In Vitro Mo el
Silibinin is the major component (50–60%) of the silymarin extract and is characterized by an
equimolar combination of two diasteroisomers, called silybin A and B [31]. The use of mice primary
hepatocytes was excluded as an attempt to reduce the nu ber of anim ls in the experimentatio .
Th s, the translation of the direct effect f silybin on huma hepatocytes was assessed in vitro, b
using stabilized hepatic cell lines. The hepatic cell lin (HuH7) (JHSRRB, Cat#JCRB0403), ob ined
from the Health Science R search Resource Bank (Osaka, Japan), was maintained in culture using
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Dulbecco’s Modified Eagle’s high glucose Medium (DMEM), supplemented with 10% v/v fetal bovine
serum, 2 mM L-glutamine, 10,000 U/mL penicillin and 10 mg/mL streptomycine, at 37 ◦C, under 5%
CO2 and in a 95% humidified atmosphere. Mycoplasma contamination has been excluded by testing
the cultures periodically using fluorescent staining (Hoechst 33258). For the induction of NAFLD, cells
were exposed for 24 h to 1200 µM of a mixture of FFA (palmitic:oleic in 1:2 molar ratio, respectively) as
previously described [30]. Silybin (Cat#1040 Extrasynthese, Genay, France) 10 mM stock solution was
prepared in DMSO. In order to assess silybin properties, cells were co-treated with FFA (1200 µM) and
different concentrations (1, 5, 7.5 µM) of silybin for 24 h. The minimal silybin concentration able to
reduce the parameters under study was 5 µM, thus this was the experimental concentration used in all
the cell treatments. The obtained data was compared vs. FFA-treated cells. For the preparation of both
FFA and FFA + silybin (FFA + SIL) DMSO was used as vehicle, so cells exposed to vehicle are referred
as Control (CTRL) in all graphs.
2.2. Intracellular Fat Quantification
Intracellular fat content in vitro was determined fluorometrically based on Nile Red staining,
a vital lipophilic dye used to label fat accumulation in the cytosol [32,33]. After 24 h of FFA exposure,
adherent monolayer cells were washed twice with PBS and detached by tripsinization. After a 5 min
centrifugation at 1500 rpm, the cell pellet was resuspended in 3 mL of PBS and incubated with
0.75 µg/mL Nile Red dye for 15 min at room temperature. Nile Red intracellular fluorescence was
determined by flow cytofluorometry using a Becton Dickinson FACS Calibur System on the FL2
emission channel through a 585 ± 21 nm band pass filter, following excitation with an argon ion laser
source at 488 nm. Data were collected in 10,000 cells and analyzed using Cellquest software from BD
Biosciences (San Jose, CA, USA).
2.3. Body, Liver, Perigonadal Adipose Tissue Weight, and Food Intake
Body weight was recorded weekly, while liver and perigonadal (epidydimal/ovarian) fat pad
tissues were dissected and weighed only at the end of the trial. Moreover, sacrificed animals’ body
weight and naso-anal length were recorded for indirect computation of body composition via body
mass index (BMI), for the confirmation of the development of the obese phenotype [34]. To exclude an
eventual effect of food-intake after the diet switch, the grams of consumed food (and the equivalent
Kcal) were recorded.
2.4. Assessment of Glucose Homeostasis, Serum Insulin, and Insulin Resistance
Glycemia and insulinemia were measured after 6 h fasting every four weeks (two days before
sacrifice), collecting few blood drops from submandibular vein (about 40 µL per animal) in local
lidocaine anesthesia. Glucose was measured in whole blood using One Touch verio IQ® meter
(Life Scan Europe, Zug, Switzerland) accordingly to manufacturer’s instructions. Serum insulin
content was quantified from the same blood sample by AlphaLISA Insulin Kit (Perkin Elmer, Waltham,
MA, USA) following manufacturer’s instructions. The homeostasis model assessment of insulin
resistance HOMA-IR was calculated for each animal according to the following formula: blood glucose
(mg/dL) × fasting insulin (µU/mL)/405 [35].
2.5. Biochemical Parameters
Total cholesterol (Chol), high-density lipoprotein cholesterol (HDL-C), and low density lipoprotein
cholesterol (LDL-C) contents were assessed. As a measurement of liver damage, serum alanine (ALT)
activity was also quantified. Enzymatic colorimetric kits (Roche Diagnostics GmbH; Mannheim,
Germany) were used to measure these parameters in a Roche HITACHI Cobas e501 instrument
(Roche Diagnostics GmbH; Mannheim, Germany) accordingly to manufacturer’s instructions by
enzymatic colorimetric assay (Roche Diagnostics GmbH; Mannheim, Germany). ALT/AST activity in
cell supernatants upon the treatments described before, were assessed by Alanine Aminotransferase
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Activity Assay Kit and Aspartate Aminotransferase Activity Assay Kit (Sigma-Aldrich®, St. Louis,
MO, USA). The amount of pyruvate and glutamate quantified with these colorimetric kits are
respectively proportional to ALT and AST enzymatic activity in each sample. The assay and the
kinetic measurements were performed following manufacturer’s instructions. The absorbance for
ALT was measured at 570 nm and for AST at 450 nm using an EnSpire® Multimode Plate Reader
(Perkin Elmer).
2.6. Histopathological Analysis
At the end of the trial, the liver was harvested and a portion of tissue immediately fixed in buffered
formalin (formaldehyde 4%, NaH2PO4 4 g/L, Na2HPO4 6.5 g/L: pH 6.8). Tissue sections were cut
at a thickness of 3.5 µm and stained with Hematoxylin & Eosin (H&E) and Gömöri trichrome stain.
Histology was read by a single independent pathologist, blinded to experimental design, and treatment
groups. Scores were attributed to steatosis (0–3), lobular inflammation (0–3), portal inflammation
(0–1), and ballooning (0–2). Fibrosis was analyzed separately with a scale from 0 to 4 according to
Kleiner–Brunt Classification [36,37].
2.7. Collagen Determination after SIRIUS Red/Fast Green Staining
The collagen content of the liver was assessed by Lopez-De Leon and Rojkind [38] colorimetric
method, using Sirius Red for the staining of collagenous proteins and Fast Green for non-collagenous
proteins. The liver was harvested and a portion of tissue immediately fixed in buffered formalin
(formaldehyde 4%, NaH2PO4 4 g/L, Na2HPO4 6.5 g/L: pH 6.8). Tissue sections were cut at a thickness
of 3.5 µm and layered on glass slides. Slices were deparaffinized after incubation with xylenes
(2 × 5 min), ethanol 100% (2 × 2 min), ethanol 95% (2 × 2 min), ethanol 70% (1 × 2 min), ethanol
50% (1 × 2 min), and distilled water (2 × 2 min). The slices were stained with Picro-Sirius Red Stain
solution (0.1% direct red 80, 0.1% fast green FCF dissolve in 1.2% aqueous picric acid solution) and
incubated for 60 min. After the staining, the slides were rapidly dipped in acidified water to destain
and finally quickly dehydrate and mount in xylene. Absorbance of stained Sirius Red collagen was
quantified after dye elution with 1 mL of 0.1% NaOH in absolute methanol (1:1). The eluted color
was read immediately in a Beckman DU 640B spectrophotometer at 540 and 605 nm, the maximal
absorbance of Sirius Red and Fast Green FCF respectively. In order to calculate the concentration of
collagen we followed the procedure reported by Lopez-De Leon and Rojkind.
2.8. Oxidative Stress Determination
2.8.1. Assessment of Lipid Peroxidation (MDA)
Malondialdehyde (MDA) is one of many low molecular weight end-products of lipid
hydoperoxide decomposition and is the most often measured as an index of lipid peroxidation [39].
Thus, oxidative stress was assessed in vivo by measuring MDA, through the generation of colored
products, after the reaction with thiobarbituric acid (TBA). Hepatic tissue was cut by medical
instruments and homogenized on ice, using 10 mM Sodium Phosphate Na3P04, 1 mM EDTA, 0.2 mM
BHT buffer. The homogenate was centrifuged at 10,000× g, 4 ◦C for 10 min and supernatant was
collected for MDA detection. Briefly, each sample was prepared by adding TBA (0.7% w/v) BHT
(2% w/v in ethanol) SDS 8.1% and acetic acid 10% v/v. After 45 min heating at 100 ◦C pink pigments
were formed. After a quick cooling process, samples were centrifuged at 10,000× g for 5 min. The
supernatant was collected and added to a same volume of TCA 10%, in order to precipitate the proteins.
The solution was vortexed and centrifuged at 15,000× g for 3 min. The supernatant was collected for
absorbance detection at 440, 532, and 600 nm. MDA was calculated using Hodges et al. equation [40].
Nutrients 2017, 9, 1006 6 of 20
2.8.2. GSH/GSSG
Reduced glutathione (GSH) is considered one of the most important scavengers of reactive oxygen
species (ROS), and its ratio with oxidized glutathione (GSSG) may be used as a marker of oxidative
stress [41]. Total glutathione (GSH) was determined in vivo by an enzymatic recycling procedure:
the sulphydryl group of the molecule reacts with 5,5′-dithiobis-2-nitrobenzoic acid (DTNB, Ellman’s
reagent) (Sigma-Aldrich, St. Louis, MO, USA) producing a yellow colored 5-thio-2-nitrobenzoic acid
(TNB), and the disulfide is reduced by NADPH in the presence of glutathione reductase.
Hepatic tissue was homogenized on ice in percloric acid solution 5%. The homogenate was
centrifuged at 10,000× g, 4 ◦C for 10 min and the acid-soluble fraction was collected and neutralized
with 2 M KHCO3. After a centrifugation to remove the formed potassium perchlorate, the supernatant
was divided to quantify both GSH and GSSG. For GSH detection, the sample was mixed with 6 mM
DTNB and 0.3 mM NADPH. After incubation at 37 ◦C for 3 min, 200 U/mL glutathione reductase was
added and immediately the rate of produced TNB was read at 415 nm using the EnSpire® Multimode
Plate Reader (Perkin Elmer, Waltham, MA, USA). Glutathione concentrations were calculated using
appropriate standards and normalized by µg of proteins.
2.8.3. Quantification of Reactive Oxygen Species (ROS)
ROS was measured in vitro by the use a cell permeable fluorogenic compound, H2DCFDA, which
is easily taken up by cells. After intracellular cleavage of the acetyl groups, this molecule becomes
substrate of the intracellular reactive species and may be oxidized to 2′,7′-dichlorofluorescein (DCF),
fluorescent product. 2 × 104 cells/cm2 were seeded in a 6-well plate and treated as described before.
After FFA and FFA+SIL exposure for 1 h and 24 h, adherent cells were washed with PBS, and were
loaded with 10 µM H2DCFDA, freshly prepared solution, for 1 h at 37 ◦C. Afterwards, cells were
lysed with 500 µL of non-ionic detergent Triton X-100 0.2% in PBS. The fluorescence of all samples was
quantified, using the EnSpire® Multimode Plate Reader (Perkin Elmer); the excitation wavelength (λex)
of DCF is 505 nm, and the emission wavelength (λem) is 525 nm. Fluorescence was normalized by µg
of protein assessed using fluorescamine, a non-fluorescent compound that rapidly reacts with primary
amines in proteins to generate highly fluorescent pyrrolinone type moieties [42]. Using a standard
curve, based on BSA serial dilutions, was calculated the amount of total protein (µg) for each sample.
Data was expressed as AUF/µg proteins.
2.9. RNA Extraction and cDNA Synthesis
For obtaining total RNA, cells and tissues were lysed with of EuroGOLD RNAPure™ (EuroClone®)
following the manufacturer’s instructions. Quantification was performed spectrophotometrically at
260 nm in a Beckman DU 640B spectrophotometer, using quartz cuvettes. The RNA purity was
evaluated by measuring the ratio A260/A280, considering RNA with appropriate purity those showing
values between 1.8 and 2.0; its integrity was evaluated by gel electrophoresis. The integrity of RNA
was assessed on standard 1% agarose/formaldehyde gel. Isolated RNA was resuspended in RNAse
free water and stored at −80 ◦C until analysis. Total RNA (1 µg) was reverse transcribed using
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to manufacturer’s
instructions. Retrotranscription was performed in a Thermal Cycler, following temperature protocol
proposed by manufactures: 10 min at 25 ◦C (annealing), 120 min at 37 ◦C (cDNA synthesis), 5 min at
85 ◦C (enzyme denaturation).
2.10. Gene Expression Analysis by Real Time RT-PCR
cDNA samples obtained from RT-PCR were used in the Real Time quantitative PCR to determine
gene expression after treatment. PCR amplification was carried out in 15 µL reaction volume containing
cDNA, 1× iQ SYBR Green Supermix, and specific sense and anti-sense primers. The exception was
TNF-α, whose amplification was carried out in 50 µL reaction volume.
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All primer pairs used for Real Time PCR were designed using the software Beacon Designer 8.10
and they were synthesized by Sigma Genosys Ltd. Primer sequences, concentrations, and ng of cDNA
used are reported in Table 1. Standard curves were prepared using a ‘calibrator’ cDNA for each target
and reference gene. In order to verify the specificity of the amplification, a melt-curve analysis was
performed, immediately after the amplification protocol. Non-specific products of PCR were found in
any case. The relative quantification was made using the Pfaffl modification of the ∆∆Ct equation [43],
taking into account the efficiencies of individual genes. The results were normalized in vivo to β-actin
and Gapdh, and in vitro to β-actin and ribosomal subunit 18S, used as reference genes. The data were
analyzed using iQ5™ optical system software Version 2.0 (Bio-Rad Laboratories Hercules, CA, USA).
Table 1. Primer pair sequences.
Mouse Genes Accession Number Forward Reverse
Gapdh NM_008084 CCAGTATGACTCCACTCACG CTCGCTCCTGGAAGATGGTG
β-Actin NM_007393 CCTTCTTGGGTATGGAATCCTGTG CAGCACTGTGTTGGCATAGAGG
Dgat-2 NM_026384 CCAAGAAAGGTGGCAGGA ATGGGAAAGTAGTCTCGGAAG
Mcp-1 NM_011333 TGTGACTCGGACTGTGAT CATTGAAAGTGTTGAATCTGGAT
Tnf-α NM_013693 AGACCCTCACACTCAGAT CTTGGTGGTTTGCTACGA
Cxcl-1 NM_008176 CATAGCCACACTCAAGAA GGACACCTTTTAGCATCT
Cxcl-2 NM_009140 ACTTCAAGAACATCCAGAG TTGAGAGTGGCTATGACT
α-Sma NM_007392.2 GGCATCAATCACTTCAAC TCTGGTCACCTGTATGTA
Col-1a1 NM_007742.3 AAGAAGACATCCCTGAAG ATACAGATCAAGCATACCT
Human Genes Accession Number Forward Reverse
β-Actin NM_001101.3 CGCCGCCAGCTCACCATG CACGATGGAGGGGAAGACGG
18S NR_003286.2 TAACCCGTTGAACCCATT CCATCCAATCGGTAGTAGCG
IL-8 NM_000584 GACATACTCCAAACCTTTCCAC CTTCTCCACAACCCTCTGC
TNF-α NM_000594 GTGAGGAGGACGAACATC GAGCCAGAAGAGGTTGAG
MCP-1 NM_002982 CCAGTCACCTGCTGTTAT CAATGGTCTTGAAGATCACA
2.11. Assessment of Apoptosis
2.11.1. In Vivo
Evidence of chromatin condensation, a marker of cell death by apoptosis, was obtained by staining
with Hoechst 33258 (Sigma Aldrich, St. Louis, MO, USA) on formalin embeded liver section. In brief,
slices were deparaffinized after incubation with xylenes (2 × 5 min), ethanol 100% (2 × 2 min), ethanol
95% (2 × 2 min), ethanol 70% (1 × 2 min), ethanol 50% (1 × 2 min), and distilled water (2 × 2 min).
The slices were then stained with 1 µg/mL Hoechst 33258 and incubated for 30 min. After the staining,
the slides were rapidly dipped in acidified water to destain and finally quickly dehydrate and mount
in xylene. Apoptotic cells were counted at 100×magnification, by fluorescence microscopy using a
Leica DM2000 (Leica Mycrosystems Srl, Solms, Germany) by three independent operators. At least
three different fields were analyzed in each sample. The results were expressed as the percentage of
apoptotic cells relative to the total number (apoptotic plus unaffected) of cells in the control (100%).
2.11.2. In Vitro
During apoptosis, Annexin-V is exposed from the inner to the outer portion of the membrane,
becoming available to bind the Annexin-V/FITC conjugate. Briefly, 2 × 104 cells/cm2 were seeded in
a 6-well plate and treated as described before. After 24 h cells were detached by gentle tripsinization,
then inactivated by medium with 10% FBS and centrifuged for 5 min at 200× g. The pellet obtained
was suspended in the binding buffer (10 mM Hepes/NaOH, pH 7.40, 140 mM NaCl, 5 mM CaCl2),
adjusting cell density to 5× 106 cell/mL. Finally, 1× 106 cell were incubated with 5 µL Annexin V-FITC
and 10 µL PI for 10 min at room temperature. Subsequently, cells were analyzed by flow cytometer
using 488 nm excitation and 515 nm band-pass filter for fluorescent detection (on FL1 and FL2 channels
for Annexin V-FITC and PI positive cells, respectively). Data were collected for 10,000 cells and
analyzed using Flowing Software 2.5.1 (Cell Imaging Core, Turku Centre for Biotechnology. University
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of Turku and Åbo Akademi University). The reported results correspond to the mean ± SD of the % of
cells in apoptosis (early + late apoptosis).
2.12. Statistical Analysis
Unless otherwise indicated, all data in vivo are reported as mean ± SD different animals of each
experimental group vs. sex and age-matched HFHC and control group. Statistical comparison between
diet groups was performed using one way ANOVA and post-hoc Tukey–Kramer’s test. A p-value of
<0.05 was considered statistically significant.
Data in vitro are expressed as mean ± standard deviation of three independent experiments
(biological replicates). Differences between groups were compared by using unpaired Student’s
t test when variables were normally distributed; conversely, when they were not, the non-parametric
Welch’s unpaired test was performed. The level of significance was set at a p-value of 0.05. The effect
of FFA+SIL was compared vs. FFA-treated cells.
3. Results
3.1. Effect on the Body, Liver, and Adipose Tissue Weight
The addition of silymarin to the HFHC diet did not induce any change in the body weight
and BMI; however, the weight of the perigonadal (epididymal/ovarian) fat pads (visceral fat) was
significantly reduced vs. the HFHC group (Table 2). Moreover, in females a reduction in the liver
weight was also observed. After the switch from HFHC to HFHC + SIL diet, a reduction in the food
intake of 35%gr (equivalent to 14% Kcal) in males and of 28%gr (7% Kcal) in females was observed.
As this difference is marginal, we exclude a differential food intake as possible effector of the observed
beneficial effects. Interestingly, the switch of diet from HFHC to CTRL completely restored the normal
values of all the parameters in both genders (except for males’ body weight, which was only slightly
reduced), whereas CTRL diet supplementation with silymarin (HFHC→CTRL + SIL) did not show
additional effects to those observed due to the change of diet.
3.2. Effect on Glucose Homeostasis
Significant alterations of the glycemia, insulinemia, and thus the HOMA-IR, were observed only
in the HFHC males; females show only hyperglycemia with no insulin resistance (IR). The addition
of silymarin to the HFHC diet significantly reduced the glucose levels. In spite of the hypoglycemic
properties of the HFHC + SIL, reversion of IR was not achieved mainly because the level of insulin
were unchanged. The switch of the diet from HFHC to CTRL improved all the parameters involved
in the glucose homeostasis, by restoring the basal levels (Table 3) independently from the addition
of silymarin.
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Table 2. Macroscopic features in males and females.
Parameters
MALES FEMALES
Control HFHC HFHC + SIL HFHC→CTRL HFHC→CTRL + SIL Control HFHC HFHC + SIL HFHC→CTRL HFHC→CTRL + SIL
Body weight (g) 29.2 ± 2.6 43.4 ± 1.8 *** 43.7 ± 4.6 34.4 ± 2.6 ### 30.3 ± 3.3 ### 23.4 ± 1.0 35.4 ± 4.3 ** 31.8 ± 3.4 23.5 ± 1.5 ## 23.9 ± 1.9 ##
BMI (kg/m2) 3.2 ± 0.3 4.8 ± 0.2 *** 4.8 ± 0.5 3.7 ± 0.3 ### 3.3 ± 0.4 2.9 ± 0.1 4.4 ± 0.5 *** 3.9 ± 0.4 2.9 ± 0.2 ### 2.9 ± 0.1 ##
Liver weight (g) 0.96 ± 0.08 1.8 ± 0.2 *** 1.8 ± 0.1 1.1 ± 0.1 ## 1.00 ± 0.04 ## 0.88 ± 0.05 1.2 ± 0.1 * 1.09 ± 0.15 # 0.9 ± 0.1 0.94 ± 0.01 ##
Perigonadal Fat Pads (g) 0.98 ± 0.08 2.4 ± 0.3 *** 2.3 ± 0.2 # 1.3 ± 0.28 ## 1.0 ± 0.4 ## 0.32 ± 0.01 1.5 ± 0.6 ** 0.9 ± 0.3 # 0.32 ± 0.09 ### 0.27 ± 0.07 ###
At the end of the trial the total body, the liver and the perigonadal fat pads weight were measured and the body mass index (BMI) was calculated. * p < 0.05 vs. CTRL; ** p < 0.01 vs. CTRL;
*** p < 0.001 vs. CTRL and # p < 0.05 vs. HFHC; ## p < 0.01 vs. HFHC; ### p < 0.001 vs. HFHC.
Table 3. Changes in glucose homeostasis.
Parameters
MALES FEMALES
Control HFHC HFHC + SIL HFHC→CTRL HFHC→CTRL + SIL Control HFHC HFHC + SIL HFHC→CTRL HFHC→CTRL + SIL
Glucose (mg/dL) 164 ± 20 260 ± 24 *** 226 ± 17 # 167 ± 13 ## 187 ± 17 ## 141 ± 10 193 ± 25 ** 181 ± 31 134 ± 6 ### 142 ± 12 ###
Insulinemia (µU/mL) 1.9 ± 0.4 4.1 ± 1.1 ** 3.6 ± 1.3 2.0 ± 1.2 ## 1.5 ± 0.7 ### 0.9 ± 0.1 2.5 ± 1.7 2.1 ± 0.5 1.3 ± 0.3 # 1.2 ± 0.4 #
HOMA-IR 1.4 ± 0.4 2.8 ± 0.7 * 2.0 ± 0.8 0.6 ± 0.1 ## 0.7 ± 0.4 ## 0.3 ± 0.004 1.3 ± 1.0 0.9 ± 0.2 0.4 ± 0.1 0.4 ± 0.2
In the table are reported the values of glycemia, insulinemia as well as de HOMA-IR after the trial. * p < 0.05 vs. CTRL; ** p < 0.01 vs. CTRL; *** p < 0.001 vs. CTRL and # p < 0.05 vs. HFHC;
## p < 0.01 vs. HFHC; ### p < 0.01 vs. HFHC.
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3.3. Effects on Lipid Profile
As previously described [29], HFHC diet induces alterations in the blood lipid profile both in
males and females by increasing total cholerterol, LDL, and HDL. The addition of silymarin to the
HFHC diet had no effects in the total cholesterol concentration. However, it significantly reduced the
LDL levels in both genders, and HDL only in males. (Figure 1A–C). The diet change (HFHC→CTRL),
restored the normal lipid profile observed in the control group. Silimarin-enriched CTRL diet did not
induce additional benefits.
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Figure 1. Effect of sily arin-containing food on the lipid profile. he a o t of ( ) total c lester l;
(B) LDL cholesterol; and (C) L cholesterol as easured in all t e e eri e tal r s. * p < 0.05
vs. CTRL; ** p < 0.01 vs. CTRL; *** p < 0.001 vs. CTRL and ◦ p < 0.05 vs. FHC; ◦◦ p < 0.01 vs. HFHC;
◦◦◦ p < 0.001 vs. HFHC.
3.4. Effect on Transaminases Activity
Asp rtate aminotransferase (AST) and alanine aminotransferase (ALT) re surr gate markers
used to assess liv r damage. In our model, HFHC diet ind ced a p ak in the activity of ALT both in
males and females (Figure 2A), herea AST activity was unchanged (data not shown). The addition of
silymarin o HFHC diet showed a statistically relevant reduction in ALT levels only in males. The diet
switch d to CTRL completely restored the basal activity levels, and the silymarin supplemen ation
did not show a synergic effect. To confirm th eff ct of silybi on the h patocyte, AST, and ALT were
measu ed the culture medium upon exposure to both to FFA and FFA+SIL. Similarly, increase of
ALT wa induced by FFA and the co-treatment with silybin exerted a protective effect vs. FFA by
reducing the amount of ALT (1.24 ± 0.5-folds, p < 0.05 vs. FFA) (F gure 2B). In line ith the in vivo
observation, AST levels were also unchanged in vitro (data not shown).
3.5. Hepatic Histological and Molecular Features Upon Silymarin Supplementation
In our model we observed that HFHC diet induced steatosis both in males and females, with a
predominant panacinar location in males and azonal in fe ales (Table 4, Figure 3A–J). All males also
presented microvescicular steatosis. The addition of silymarin to the HFHC diet had a modest effect in
the reduction of the steatosis score in males, and no effect in females. This observation was in agreement
with the in vitro experiments where FFA + SIL did not shown differences in the intracellular content
vs. FFA treated cells (data not shown). The histological scoring of the portal/lobular inflammation
showed no changes in males, whereas in females silymarin seems to reduce the lobular inflammation.
As for the other parameters, diet switch from HFHC to CTRL (HFHC→CTRL) (independently from
the supplementation with silymarin) restored the basal levels observed in the control group.
Nutrients 2017, 9, 1006 11 of 20Nutrients 2017, 9, 1006 11 of 21 
 
 
Figure 2. Assessment of the ALT activity. The ALT activity was measured (A) in vivo in all the 
experimental groups and confirmed (B) in vitro on fat-laden human hepatocytes (HuH7). ** p < 0.01 
vs. CTRL; *** p < 0.001 vs. CTRL and p < 0.05 vs. HFHC/FFA; p < 0.01 vs. HFHC; p < 0.01 vs. HFHC. 
Table 4. Histological features. 
 MALES FEMALES 



























2 (80%) 2 (100%) 
1 (75%) 
2 (25%) 2(100%) 














































































Histological analysis according to Brunt’s classification. Data is expressed as score/grade and between 
brackets the occurrence.  
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Histological analysis according to Brunt’s classification. Data is expressed as score/grade and between brackets
the occurrence.
The most interesting finding of our study is the effect of the addition of silymarin to the HFHC
diet in the regression of fibrosis. While a mild periportal fibrosis (score 1a) was also observed in
controls, the HFHC diet group showed a worsening of the fibrosis stage towards a portal/periportal
fibrosis (sc re 1c) in 40% of males and 60% of femal s. The group of HFHC + SIL i b t genders
showed a reduction of fibrosis with a predo inant score of 1a in the majority of the animal (Table 4.
Figure 3K–O). Subsequently, the c llagen content i the liver slices was quantified by Sirius Red/Fast
Green taining (Figure 3P–T) As shown in Figure 3U w observed a 1.3- olds reduction in the collagen
content in the HFHC + SIL group vs. HFHC diet in both genders. The histopat olog cal findings
were confirmed further by the mol cular analysis of the hepatic col agen (Col1a1) gen expression.
Both males and females showed an increased expression of collagen induced by HFHC iet, whereas i
both gend rs a two-fold reduction was observed by the ad itio of silymarin (Figure 3V). Interestingly,
we observed that even if collagen was upregulated in both genders exposed o HFHC diet, only females
showed a sustained a-Sma up-regulation (hep tic stellate cells (HSC) activation marker). Its expression
in his group was restored to he basal levels by silymarin nrichm nt (Figure 3W). Th s finding
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histological and molecular features upon silymarin supplementation. 
Molecular analysis of pro-inflammatory mediators showed that HFHC+SIL is effective to 
decrease the gene expression both of Cxcl-1 and Cxcl-2 (murine homologous of human IL8) (Figure 
4A,B); Mcp-1 (only in males) (Figure 4C) while has no effect on the expression of Tnf-α either in males 
or in females (Figure 4D). The in vitro data showed that hepatocytes co-treated with FFA+SIL showed 
IL-8 and TNF-α expression returned to basal levels (Figure 4E–F). Interestingly, hepatocyte 
expression of MCP-1 was under the detection limit and was not induced by FFA exposure (data not 
shown). As mentioned before, also in this case the switch of HFHC to CTRL diet (independently of 
the presence of silymarin) restored the basal levels of all the parameters under study. 
Figure 3. Hepatic histological and molecular features upon silymarin supplementation. Representative
slices of liver samples stained with hematoxylin-eosin staining (A–E), with higher magnification of
the dashed area (F–J). Gömöri Staining for fibrosis assessment (K–O). Collagen staining was done by
Sirius Red/Fast Green staining (P–T). The µg of collagen was quantified in all groups and normalized
by mg/protein (U). The mRNA gene expression of Col1a1 (V) and α-Sma (W) were was assessed by
RT-PCR. * p < 0.05 vs. CTRL; ** p < 0.01 vs. CTRL; *** p < 0.001 vs. CTRL and ◦ p < 0.05 vs. HFHC;
◦◦ p < 0.01 vs. HFHC; Hepatic histological and molecular features upon silymarin supplementation.
Molecular analysis of pro-inflammatory mediators showed that HFHC + SIL is effective to decrease
the gene expression both of Cxcl-1 and Cxcl-2 (murine homologous of human IL8) (Figure 4A,B); Mcp-1
(only in males) (Figure 4C) while has no effect on the expression of Tnf-α either in males or in females
(Figure 4D). The in vitro data showed that hepatocytes co-treated with FFA+SIL showed IL-8 and
TNF-α expression returned to basal levels (Figure 4E–F). Interestingly, hepatocyte expression of MCP-1
was under the detection limit and was not induced by FFA exposure (data not shown). As mentioned
before, also in this case the switch of HFHC to CTRL diet (independently of the presence of silymarin)
restored the basal levels of all the parameters under study.
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i of the metabolic syndrome, and is con idered one of the major triggers of the progression
of the damage. ROS generation was assessed i liver homogenates throug the quan ification of MDA
and GSH/GSSG ratio. A significant MDA increment was observed o ly in HFHC femal s (Figure 5A),
while males did not show any difference (data not shown). This alterati n was mirrored also by
the GSH/GSSG ratio that followed the same pattern (Figure 5B). The addition of silymarin to the
HFHC diet induc d a partial reduction of MDA levels vs. the HFHC group, even if the reduction was
not statistically significant (p = 0.06). Interes ingly, within thi group (HFHC + SIL females) it was
possible to identify two sub-groups: responders (HFHC + SIL R) and non-respo ers (HFHC + SIL
NR) (Figure 5A). Addition of silymarin to the HFHC diet restored the hepatic redox equilibrium as
ind cated by GSH/GSSG ratio. The ability of silybin to counteract the FFA-indu ed oxidative str ss
was obs rved also in vitro. After 1 h silybin promotes a reduction (27.5 ± 10.0%, p < 0.05) in ROS
generation (Fi ure 5C) whereas no differences were observed at 24 h, c nfirming oxidative stress in an
early cellular respo s .
Also in this case, switch from HFHC to control diet (CTRL) led to a reduction of MDA levels,
decreased the lipid peroxidation, and improved the GSH/GSSG ratio, confirming the antioxidant
benefits of this therapeutic approach. Also, in this case, no synergic effect was observed with the
enrichment of silymarin in the HFHC→CTRL + SIL group.
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Figure 5. Assessment of antioxidant properties of silymarin formulation. The redox state was calculated
in vivo as the amount of lipoperoxides (MDA) (A) and the cellular antioxidant properties measured as
the glutathione ratio (GSH/GSSG) (B). Whereas, in vitro were measured the total amount of reactive
oxygen speci s (C). * p < 0.05 vs. CTRL; ◦ p < 0.05 vs. HFHC; ◦◦ p < 0.01 vs. HFHC.
3.7. Anti-Apoptotic Effect
Apoptosis is one of the events that participates in the progression of simple steatosis to
steatohepatitis [44]. In our model we observed an induction of apoptosis (28% ± 4%, p < 0.001)
in the HFHC vs. CTRL group (Figure 6A) in males whereas females did not present changes in the
number of apoptotic cells (data not shown). The addition of silymarin significantly reduced the cells
in apoptosis restoring the CTRL group levels. Also in this case the switch from HFHC to CTRL diet
fully reverted the damage. In line ith this observation, cells ex ed to FFA showed a significant
increment in apoptosis (27.85 ± 5.29%, p < 0.01 vs. CTRL cells). Co-treatment of FFA+SIL reduced
the number of apoptotic cells (10.12 ± 7.9%, p < 0.05 vs. FFA), restoring the basal levels as CTRL cells
(Figure 6B). These data indicate that silybin effectively counteracts the lipoapoptotic mechanism.
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Figure 6. Effect of silymarin formulation on a o tosis. The number of cells undergoing apoptosis was
counted in vivo (A) and in vitro (B). ** p < 0.01 vs. CTRL; *** p < 0.001 vs. CTRL; ◦ p < 0.05 vs. HFHC;
◦◦◦ p < 0.001 vs. HFHC.
4. Discussion
Over the last 40 years, the obesity outbreak has been challenging the worldwide care system [45].
It has been reported that obesity is tightly associated with the incidence of NAFLD [46,47]. NALFD
is the most common cause of liver disease in the pediatric population with a prevalence of 10.2%
in Asians; 1.5% in Blacks; 11.8% Hispanic; and 8.6% in Caucasians [48]. While in adults NAFLD
Nutrients 2017, 9, 1006 15 of 20
is considered a benign, potentially reversible, and slow progressive liver disease, in children it can
progress rapidly to NASH reaching end-stage liver disease during adolescence [48,49]. In spite of this
alarming evidence, to date there are no approved pharmacological therapies for NAFLD neither in
children nor in adults. The best and most effective option still relies on lifestyle modifications including
nutrition [7], exercise [6], and dietary supplements [50]. However, patients’ compliance is very low
towards these approaches and usually there is a poor long-term success rate [51]. The use of dietary
supplements as complementary and alternative medicine represents an appealing and fertile field
of study; unfortunately, data published so far did not fulfill the expectations (extensively reviewed
elsewhere [28]).
Silymarin extract has been used since ancient times in the treatment of various liver
disorders [11,12]. Based on this evidence, silymarin has become an interesting therapeutic candidate
for NAFLD. Data from animal models are promising, and it has been demonstrated that silymarin
exerted positive effects in improving many of the pathological features of NAFLD. Unfortunately,
the translation to the human scenario is unfeasible mainly because the studies reporting beneficial
effects were conducted in animals where silymarin had been administrated intraperitoneal or by
gastric gavage (reviewed elsewhere [27]). The oral administration of silymarin is hampered by low
solubility in water, poor intestinal absorption and, consequently, its low and poorly predictable
bioavailability [52]. The combination of milk thistle extracts with solubilizing substances can improve
this aspect. In the present study, we explored the effects of the addition of silymarin to the western
diet (HFHC), thus administrated orally. For this purpose, a special food formulation was prepared
taking advantage of the ingredients already present into the diet to facilitate silymarin solubility.
One of our main goal was to assess (as physiologically as possible) the effect of the
silymarin-enriched food in an obesogenic condition, using a juvenile murine model of NASH.
Conversely to other studies in which adult mice were used, in the present study the animals were fed
immediately after weaning for a total of 20 weeks (equivalent to human 3–30 years old [53]). Since we
previously reported [29] a sex-related difference in NAFLD onset and in progression to NASH, in this
work we investigated a possible sex dimorphism in the therapeutic response.
The HFHC + SIL diet improved many of the crucial parameters involved in the progression of
NAFLD. For instance, silymarin-enriched food reduced the visceral fat in both genders, with no effect
on the total body weight. In agreement with our observation, it has been has been recently reported [54]
that dietary silymarin supplementation significantly reduced the elevated intraperitoneal fat index in
grass carp fed with high-lipid diets. This study also showed that silymarin decreases the expression
of the adipogenic genes Ppar γ, C/Ebp α, Srebp1c, Fas, Scd1, and Lpl. HFHC + SIL also improved the
hepatomegaly in females, whereas in males reduced the ALT activity. Our study demonstrates that
HFHC diet induced IR only in males. Silymarin slightly reduced the glucose but not insulin level,
and thus not improving IR. This observation leads to questioning the real efficacy of silymarin in the
reversion of the alterations in glucose homeostasis.
The most evident effect of HFHC + SIL on lipid profile was the reduction of LDL-cholesterol in
both genders, with no statistically relevant changes in the total cholesterol levels. This observation is
particularly interesting due to the involvement of LDL cholesterol in arteriosclerosis and cardiovascular
disease [55]. There is a popular designation of HDL as ‘the good cholesterol’ due to the inverse
correlation with coronary heart disease risk. However, paradoxically, diets high in saturated fat and
cholesterol which increase atherosclerosis risk also raise HDL levels [56]. This increase in HDL was
also observed in the HFHC group, whose levels were restored to control values after life-style changes
(group switched from HFHC to CTRL). The addition of silymarin to the HFHC diet (HFHC + SIL)
induced a reduction of HDL vs. the values observed in the HFHC littermates.
Even if in the present study we did not perform bioavailability tests, we did observe
hepatoprotective effects by the oral consumption of the formulation of western diet containing
silymarin, suggesting that silymarin was absorbed. These observations were further confirmed
in vitro by the direct exposure of human hepatocytes to silybin+FFA.
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We observed that HFHC + SIL diet exerted an anti-inflammatory effect inducing a reduction in
the hepatic expression of some cytokines (Cxcl-1 and Cxcl-2 (murine IL-8 homologous) in both genders,
and Mcp-1 only in males. These changes had no relevant effects on the histological inflammatory
activity score. The anti-inflammatory effect of silybin was confirmed in vitro with a similar pattern of
downregulation in the gene expression of IL-8 and TNF-α on the hepatocytes. Since levels of MCP-1 in
hepatocytes were under the detection limit, it is tempting to speculate that the downregulation of this
cytokine observed in the males might be a consequence of the effect of the silymarin on other hepatic
cell types. It is well-known that MCP-1 expression is related to the number of monocytes infiltrated
and is an important mediator for the progression to NASH [57]. Also IL-8, once secreted, acts as a
potent chemoattractant for neutrophils and leukocytes recruitment [58].
Oxidative stress is recognized as a driving force in the onset and the progression of NAFLD.
Since the HFHC diet induced hepatic oxidative stress only in females [29], the eventual
anti-oxidant properties of the silymarin-enriched formulation were assessed only in females. Some
females reverted the amount of hepatic lipoperoxides (MDA) and the entire group showed a
GSH/GSSG ratio significantly improved by the addition of silymarin to the HFHC diet. Silybum
marianum extract has high polyphenolic content that leads to a well-recognized antioxidant effect
through free radical scavenging [59]. The reduction of ROS generation determines the attenuation
of lipid peroxidation, observed in our model with a partial MDA decrease and with the increase
of hepatic GSH content. It has been demonstrated that silymarin is able to regulate GSH content
with organ-specific action [60]. Based on the short half-life of silymarin, the liver is its main target,
the principal site of silymarin accumulation and the starting point for a cyclic transportation via
entero-hepatic circulation. As a result, the liver (together with the stomach and the intestine) is the
tissue receiving the higher silymarin amount that justifies the large increase in GSH concentration.
In line with these findings, in vitro data clearly showed how the co-treatment of silybin+FFA is able
to counteract the ROS generation induced by FFA. All together these data indicate that silymarin
formulation is able to reduce the HFHC-induced oxidative stress.
We observed a clear gender difference in the induction of lipo-apoptosis. HFHC diet had a potent
pro-apoptotic effect in males whereas in females this feature was absent. Hence, the assessment of the
anti-apoptotic effect of the silymarin formulation was only possible in males, in which HFHC + SIL
diet significantly reduced the number of apoptotic cells. It has been extensively reported the activity of
silymarin on the activation of pro-caspase 3 [61], involved in the binding to death receptor of Fas/tumor
necrosis factor receptor family and formation of death inducing signal complex [62]. The anti-apoptotic
effect of silymarin was also confirmed in vitro. Human fat-laden hepatocytes showed an increased
generation of ROS that was successfully reduced by silymarin treatment.
We reported previously [29] that our juvenile model of NASH presented a time-dependent
progressive fibrosis with a histological score of 1c–2 after 16 weeks of HFHC diet. To our knowledge,
this is the only DIO model showing this degree of liver fibrosis in such a short time frame. The most
relevant finding of the present study is the effect of HFHC + SIL on this feature. Herein we observed
an improvement in the histological liver fibrosis score in both genders, it is likely that with longer
exposure times to silymarin formulation the extent of improvement would be higher. This observation
was also confirmed in terms of collagen gene expression and extracellular protein deposition. The onset
of a sustained inflammation and oxidative stress typical of NASH increases the risk of progression to
advanced fibrosis. In the cytosol, the release of cytokines initiates intracellular signaling (via NF-kB)
with the final activation of HSC [63]. Silymarin is able to counteract the inflammatory milieu
mainly by suppressing NF-kB activation [64] and thus prevent the following pro-fibrogenic processes.
This finding is particularly relevant as fibrogenesis is a crucial step in the progression from NAFL
to NASH and, consequently, in the severity of the liver disorder. Furthermore, it has been recently
described that no other histological features but fibrosis are associated with the long-term outcomes
of patients with NAFLD [65]. For these reasons, the silymarin food formulation used in this study
presents many promising perspectives.
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In the present study, we assessed also the effect of lifestyle changes in the reversion of the
pathological features induced by HFHC diet. In line with previous data, the diet switched from
HFHC to CTRL diet improved/reverted all the parameters under study. We also explored if
silymarin supplementation would provide a synergic beneficial to lifestyle changes, however our
data showed that the overall improvement was mainly due to diet changes independent from the
silymarin supplementation.
5. Conclusions
The novelty of the present work relies on the addition of silymarin to the western diet as an
alternative approach to counteract/revert the damage induced by the excess in the consumption of fat
and sugars. The experimental model used represents a diet-induced model of obesity able to reproduce
many of the features involved in the onset of NAFLD. The particularity of this experimental model is
that it covers the ages from the weaning to the adulthood. Translated to humans, it covers the range
from 3 to 30 years old, which represents the period where the incidence of obesity is reaching epidemic
values [66]. Although the beneficial effect of the formulation present a sexual dimorphism, silymarin
was able to improve the liver condition (especially fibrosis) both in males and females.
The use of silymarin in children has been previously tested in pediatric population in the context
of other pathologies, with no reported collateral effects [67,68]. Consequently, silymarin can be safely
tasted in this population. Nevertheless, to our knowledge, currently there is no planned clinical trial
for pediatric NASH [69].
All together, we consider that the data provided represent a valid strategy for the future
development of dietary supplements containing silymarin. These approaches represent an alternative
to overcome patients’ low compliance to diet changes in the field of NAFLD/NASH.
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